Pre-exposure prophylaxis (PrEP) could reduce new cases among men who have sex with men (MSM) by a third in the United States over the next 10 years (J Infect Dis 2016 Jul 14. [Epub ahead of print]).
The drop in HIV incidence, however, would depend on clinicians prescribing the medication according to federal guidelines and on patients using it as directed.
A combination of two HIV drugs, emtricitabine and tenofovir (Truvada, Gilead), was approved by the FDA for daily use as PReP
JULY 15, 2016